Safety and efficacy of regorafenib post-marketing surveillance (PMS) in Japanese patients with metastatic colorectal cancer (mCRC).

被引：5
|
作者：
Komatsu, Yoshito
Muro, Kei
Yamaguchi, Kensei
Satoh, Taroh
Uetake, Hiroyuki
Yoshino, Takayuki
Nishida, Toshirou
Takikawa, Hajime
Kato, Takeyuki
Chosa, Masayuki
Sunaya, Toshiyuki
Yamamoto, Yuka
Hamada, Yoko
Watanabe, Toshiaki
Sugihara, Kenichi
机构：
[1] Hokkaido Univ Hosp, Ctr Canc, Sapporo, Hokkaido, Japan
[2] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[3] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol, Tokyo, Japan
[4] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, Osaka, Japan
[5] Tokyo Med & Dent Univ, Dept Surg Specialties, Tokyo, Japan
[6] Natl Canc Ctr Hosp East, Chiba, Japan
[7] Natl Canc Ctr, Tokyo, Japan
[8] Teikyo Univ, Sch Med, Tokyo, Japan
[9] Bayer Yakuhin Ltd, Tokyo, Japan
[10] Bayer Yakuhin Ltd, Osaka, Japan
[11] Univ Tokyo, Grad Sch Med, Dept Surg Oncol, Tokyo, Japan
[12] Tokyo Med & Dent Univ, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.721
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
721
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Safety and efficacy of regorafenib in Japanese patients with metastatic colorectal cancer (mCRC) in clinical practice: Interim result from postmarketing surveillance (PMS).
    Komatsu, Yoshito
    Muro, Kei
    Yamaguchi, Kensei
    Uetake, Hiroyuki
    Satoh, Taroh
    Yoshino, Takayuki
    Nishida, Toshirou
    Yamazaki, Naoya
    Takigawa, Hajime
    Hamada, Yoko
    Chosa, Masayuki
    Sunaya, Toshiyuki
    Yamamoto, Yuka
    Ito, Yuichiro
    Watanabe, Toshiaki
    Sugihara, Kenichi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [2] A JAPANESE POST-MARKETING SURVEILLANCE OF REGORAFENIB IN COLORECTAL CANCER PATIENTS: INTERIM REPORT
    Satoh, Taroh
    Yamazaki, Naoya
    Takikawa, Hajime
    Ito, Hideyuki
    Ito, Yuichiro
    Sakaguchi, Toshiaki
    Yamada, Takashi
    Muro, Kei
    Sugihara, Kenichi
    [J]. ANNALS OF ONCOLOGY, 2014, 25
  • [3] A Japanese Post-marketing Surveillance of Cetuximab (Erbitux) in Patients with Metastatic Colorectal Cancer
    Ishiguro, Megumi
    Watanabe, Toshiaki
    Yamaguchi, Kensei
    Satoh, Taroh
    Ito, Hideyuki
    Seriu, Taku
    Sakata, Yuh
    Sugihara, Kenichi
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (04) : 287 - 294
  • [4] Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance
    Watanabe, Jun
    Terazawa, Tetsuji
    Yamane, Shiho
    Kazama, Hirotaka
    Uetake, Hiroyuki
    Yoshino, Takayuki
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (01) : 130 - 138
  • [5] Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance
    Jun Watanabe
    Tetsuji Terazawa
    Shiho Yamane
    Hirotaka Kazama
    Hiroyuki Uetake
    Takayuki Yoshino
    [J]. International Journal of Clinical Oncology, 2023, 28 : 130 - 138
  • [6] Final safety results from the post-marketing survey (PMS) of bevacizumab (BV) in Japanese colorectal cancer patients
    Doi, T.
    Shirao, K.
    Uetake, H.
    Hatake, K.
    Takahashi, Y.
    Nihira, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Post-marketing surveillance study of trifluridine/tipiracil in patients with metastatic colorectal cancer
    Yoshino, Takayuki
    Uetake, Hiroyuki
    Funato, Yuya
    Yamaguchi, Yasunobu
    Koyama, Takahiko
    Ozawa, Daisuke
    Tajiri, Masaru
    Muro, Kei
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (05) : 700 - 706
  • [8] A post-marketing safety study of ramucirumab with FOLFIRI in patients with metastatic colorectal cancer
    Masuishi, Toshiki
    Nagaoka, Soshi
    Jin, Long
    Yoshizawa, Kenichi
    [J]. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (04) : 1701 - +
  • [9] Panitumumab in Japanese Patients with Unresectable Colorectal Cancer: A Post-marketing Surveillance Study of 3085 Patients
    Boku, Narikazu
    Sugihara, Kenichi
    Kitagawa, Yuko
    Hatake, Kiyohiko
    Gemma, Akihiko
    Yamazaki, Naoya
    Muro, Kei
    Hamaguchi, Tetsuya
    Yoshino, Takayuki
    Yana, Ikuo
    Ueno, Hiroshi
    Ohtsu, Atsushi
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (03) : 214 - 223
  • [10] Clinical safety and efficacy of "filgrastim biosimilar 2" in Japanese patients in a post-marketing surveillance study
    Tamura, Kazuo
    Hashimoto, Kazue
    Nishikawa, Kiyohiro
    [J]. JOURNAL OF INFECTION AND CHEMOTHERAPY, 2018, 24 (05) : 363 - 369
12345